Biohaven Ltd. logo

BHVNBiohaven Ltd.

NYSE · Healthcare · Biotechnology

$15.31

-$0.43 (-2.73%)

Biohaven Ltd. (BHVN) is a biotechnology company listed on NYSE. It is led by Vladimir Coric M.D., based in 215 Church Street, New Haven, CT, United States, 06510, with about 274 employees. Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Net income was -$173.4M. BHVN currently screens at market cap $1.66B.

Use this BHVN page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BHVN quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BHVN SEC filings page. Lician reads the product cache first so this HTML stays unique to Biohaven Ltd. even when a live quote feed is slow.

About Biohaven Ltd.

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

BHVN Key Statistics

Market Cap

$1.66B

Volume

3.44M

Previous Close

$13.68

Day Range

$13.92$14.86

00

EPS

-$9.28

Revenue

$0.00

Net Income

-$846.42M

Gross Profit

$0.00

Free Cash Flow

$0.00

Employees

274

BHVN Financials

Annual income statement in USD. Latest reported periods first.

BHVN annual income statement across FY2024, FY2023, FY2022, FY2021
LineFY2024FY2023FY2022FY2021
Revenue$0.00$0.00$0.00$0.00
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00$0.00
Net Income-$846.42M-$408.17M-$570.28M-$213.80M
EPS (Diluted)-$9.28-$5.73-$12.75-$5.43

Total Assets

$615.11M

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$99.13M

Operating Cash Flow

-$582.45M

Free Cash Flow

$0.00

Biohaven Ltd. Company Information

Chairman & CEO
Vladimir Coric M.D.
Headquarters
215 Church Street, New Haven, CT, United States, 06510
Phone
203 404 0410
IPO / Founded
2022-09-23
Industry
Biotechnology
Data Updated:

Upcoming Events for BHVN